Latest Biotechnology, Pharmaceutical and Healthcare News

13:15 EDT 3rd August 2015 | BioPortfolio

Showing News Articles 1–25 of 410,000+

Monday 3rd August 2015

Lexicon Share Spike On Carcinoid Syndrome Phase III Data

If successful, the company claims, telotristat etiprate would be the first oral treatment developed for carcinoid syndrome and the first addition to the standard of care (somatostatin analog depot injection) in more than 16 years.

Takeda's myeloma drug ixazomib is 'most important' launch expected in 2016

Ixazomib, a second generation small molecule proteasome inhibitor, has not yet been filed for regulatory assessment in Europe but Takeda expects to follow with this action "in the coming weeks."

Palliative chemotherapy may harm patient’s quality of life

Chemotherapy for end-stage cancer does not improve, and may harm, a patient’s quality of life in their final week of life, report researchers.

Pfizer teams with Synthon on generic Copaxone

Synthon has filed an application for a generic version of Teva's improved 40mg/mL dosage of the multiple sclerosis drug.

22nd Century Group to File Second Quarter 2015 Financial Results And Announces Conference Call to Provide Business Update

22nd Century Group, Inc. (NYSE MKT:XXII) announced today that the Company will file its second quarter 2015 report on Form 10-Q this week with the U.S. Securities and Exchange Commission and will provide a business update for investors on a conference call to be held Wednesday, August 5th, at 10:00 AM (EDT). Henry Sicignano III, President and Chie...

Shire adds to ophthalmics portfolio with buy of Foresight Biotherapeutics

Ireland-based drugmaker Shire today revealed that it has acquired New York-based, privately held Foresight…

NeuroMetrix Reports Expanding Media Exposure for Quell™ Wearable Pain Relief Technology

NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported that Quell, launched in June 2015, is receiving broad media attention. Quell is an over-the-counter wearable pain re...

Sorrento in-licenses late-stage clinical biobetter and biosimilar antibodies

Sorrento Therapeutics has entered into an exclusive licensing agreement to develop and commercialize…

New hepatitis C combination treatment effective in HIV coinfected patients

Patients with both hepatitis C virus and HIV responded well to daclatasvir combined with sofosbuvir in a study.

UC Irvine to Exhibit Artwork Created Via Biological Engineering

(Los Angeles Times) – UC Irvine has put out a call for artists who want to manipulate the building blocks of life as we know it to create art as we’ve never known it – works made of living organisms … Read More

Dechra Pharmaceuticals (DPH) - Proposed acquisition of Genera vaccine business

Edison Investment Research - Pharmaceutical & Healthcare - Dechra Pharmaceuticals: Dechra Pharmaceuticals is acquiring 63.3% of Genera, a Croatia-listed animal health business, for €23.66 a share. Genera has a strong presence in farm animal products in the region, although the primary appeal is its growing expertise in vaccines, particularly in poultry. Although the deal is expected to be ea...

Pfizer to acquire US rights for Synthon’s generic Copaxone

US pharma giant Pfizer has acquired the exclusive commercialization rights in the USA to glatiramer acetate,…

Vitamin D may not benefit postmenopausal bone health

(Reuters Health) - High doses of vitamin D may not help strengthen bones in postmenopausal women, a study suggests.

Clovis Oncology files for rociletinib approval in USA and Europe

Shares of Clovis Oncology gained nearly 2% to $86.21 in early trading today, when the company announced…

Bark at the Park Presented by AvoDerm Natural Pet Foods, Nylabone and ADAMS Celebrates a Decade of Success in Oakland

Central Garden & Pet brands, AvoDerm® Natural Pet Foods, Nylabone® and ADAMS® are marking the 10th anniversary of their partnership with the Oakland Athletics on August 6th as they present Bark at the Park. This unique event is part of a season-long campaign with eight Major League Baseball™ teams, including the A’s, that helps promote pet adopt...

Lexicon and Ipsen's telotristat etiprate Phase III trial meets primary endpoint

Lexicon Pharmaceuticals and its partner Ipsen have announced positive results from their TELESTAR Phase…

Mutation Alert Halts Stem-Cell Trial to Cure Blindness

(New Scientist) – A pioneering stem-cell trial has been halted after genetic mutations were discovered in the cells of the second trial participant. One of the mutations may carry a remote risk of cancer.The trial is the first to explore …...

Amarantus partners with US Army Institute to develop treatment for severe wound conditions

Amarantus BioScience on Monday said it has partnered with the US Army Institute of Surgical Research…

Common dementia drugs could cause harmful weight loss

Drugs commonly used to treat dementia could result in harmful weight loss, according to UC San Francisco…

Teva buys 51% equity share of Immuneering Corp.

Lesley ThulinTeva Pharmaceutical Industries Ltd. on Monday announced that it will buy a 51% equity share of Immuneering Corp., a genomic-analysis company. read more

Taking a Trip through the Brain

(Nanotechnology Now) – A new imaging tool developed by Boston scientists could do for the brain what the telescope did for space exploration. In the first demonstration of how the technology works, published July 30 in the journal Cell, the ...

Teva buys 51% stake in US co Immuneering for $60m

The acquisition gives Teva exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS.

Surrogacy Has Been Labeled “Reproductive Tourism” by a Swiss Court

(Quartz) – In 2011, two Swiss men who lived in the US registered their partnership. Two months later, they had a child through a surrogate mother in California, and according to the law were both recognized as fathers of the … Read More

Cedars-Sinai Expands Footprint with Leased Office Space at Runway Playa Vista

Leading health care provider to establish significant presence within new mixed-use development, enhancing access to its services throughout the area Cedars-Sinai is enhancing its footprint in Southern California with a brand-new regional office at Runway Playa Vista. Cedars-Sinai has signed an 11-year lease for the entire 32,000-square-foot Class A co...

TexanPlus® Champions Competition Begins Online Voting

Southeast Texas Residents Will Choose Grand Champion; Designated Charity Wins $25,000 Vote at www.TexanPlusChampions.com through September 18th TexanPlus®, a leading local Medicare Advantage health plan, announced Monday the five finalists in the TexanPlusChampions Competition and said online voting is underway to determine t...



Advertisement
 
Advertisement
 

BioPortfolio's biotechnology, pharmaceutical, healthcare and medical device information service collates press releases, news articles and blogs from over 275 sources.